White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system

Journal of the American Pharmacists Association

Volumn 49, Issue 6, 2009, Pages 729-743

  Lofton, Judy Crespi ^a  

^a JCL Communications   (United States)

Author keywords

Food and Drug Administration; Health care administration; Health care providers; Patient accountability; Patient education; Pharmacists; Provider education; Quality of care; REMS; Risk evaluation and mitigation strategies; Risk management; Workflow

Indexed keywords

ARTICLE; DRUG TOXICITY; HEALTH CARE DELIVERY; HUMAN; INFORMED CONSENT; METHODOLOGY; PATIENT EDUCATION; REGISTER; RISK ASSESSMENT; RISK MANAGEMENT;

DELIVERY OF HEALTH CARE; DRUG TOXICITY; HUMANS; INFORMED CONSENT; PATIENT EDUCATION AS TOPIC; REGISTRIES; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 75349103708     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.09541     Document Type: Article

References (18)

1. U.S. Food and Drug Administration. A guide to drug safety terms at FDA. Accessed at www.fda.gov/downloads/ForConsumers/ConsumerUpdates/ucm107976.pdf, September 18, 2009.
2. Morris LA. The risk revolution: an examination of the regulatory environment. J Am Pharm Assoc. 2001;41(suppl 1):S5-10.
3. Medication guides for prescription drug products. 21 CFR §208; 2009.
4. U.S. Food and Drug Administration. Questions and answers about Lotronex (11/29/2000). Accessed at www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsand-Providers/ucm110887.htm, August 3, 2009.
5. Leiderman DB. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Drug Alcohol Depend. March 21, 2009 [Epub ahead of print].
6. Bastani B, Alphs LD, Meltzer HY. Development of the Clozaril Patient Management System. Psychopharmacology. 1989;99(suppl):S122-5.
7. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-11.
8. U.S. Food and Drug Administration. A synopsis of the elements of the S.T.E.P.S. program. Accessed at www.fda.gov/OHRMS/DOCKETS/AC/04/briefing/4017B1- 06b%20Overview%20STEPS%20Section%20C%20Tab%207.pdf, August 14, 2009.
9. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med. 2006;3:e483.
10. U.S. Food and Drug Administration. Briefing document for iPLEDGE year one update. Accessed at www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4311b1-02- ipledge.pdf, July 6, 2009.
11. Leiderman DB. Risk evaluation and mitigation strategy (REMS) for controlled substances. Accessed at www.fdli.org/conf/handouts/Leiderman.pdf, August 12, 2009.
12. Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. Accessed at www.iom.edu/CMS/3793/26341/ 37329.aspx, August 11, 2009.
13. Food and Drug Administration Amendments Act of 2007. PL 110-85, 121 Stat 823.
14. U.S. Food and Drug Administration. Identification of drug and biological products deemed to have risk evaluation and mitigation strategies for purposes of the Food and Drug Administration Amendments Act of 2007. Fed Regist. 2008;73:16313-4.
15. U.S. Food and Drug Administration. Risk evaluation and mitigation strategies for certain opioid drugs; notice of public meeting. Fed Regist. 2009;74:17967-70.
16. Lee LY, Kortepeter CM, Willy ME, Nourjah P. Drug-risk communication to pharmacists: assessing the impact of risk-minimization strategies on the practice of pharmacy. J Am Pharm Assoc. 2008;48:494-500.
17. U.S. Food and Drug Administration. Minutes of the Risk Communication Advisory Committee, FDA. Accessed at www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/RiskCommunicationAdvisoryCommittee/UCM152593.pdf, August 31, 2009.
18. U.S. Food and Drug Administration. Providing effective information to consumers about prescription drug risks and benefits; public workshop. Fed Regist. 2009;74:33265-7.